welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
not yet recruiting

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

key information

study id #: NCT03340675

condition: Duchenne Muscular Dystrophy Cardiomyopathy

status: not yet recruiting

purpose:

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD.

intervention: Ifetroban, Placebos

mechanism of action: Thromboxane receptor antagonist to prevent cardiac function deterioration

results: https://clinicaltrials.gov/ct2/show/results/NCT03340675

last updated: February 04, 2020